Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind active-controlled trial of a serum-free MRC-5 cell rubella live attenuated vaccine in adults aged 18-50 years
CTR20221293Phase 3Active
- Sponsor
- Tianjin Jinster Vaccine
- Start
- Feb 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of rubella vaccine, live in rubella, sponsored by Tianjin Jinster Vaccine. Started Feb 2023; status: active.
02
Drugs
rubella vaccine, live
03
Conditions
rubella
Beyond the preview
Go deeper on CTR20221293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221293.